These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

531 related articles for article (PubMed ID: 32156227)

  • 21. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease.
    Budd J; Cusi K
    Curr Diab Rep; 2020 Oct; 20(11):59. PubMed ID: 33015726
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Established and emerging factors affecting the progression of nonalcoholic fatty liver disease.
    Kechagias S; Nasr P; Blomdahl J; Ekstedt M
    Metabolism; 2020 Oct; 111S():154183. PubMed ID: 32061907
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
    Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
    Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation.
    Younossi ZM; Marchesini G; Pinto-Cortez H; Petta S
    Transplantation; 2019 Jan; 103(1):22-27. PubMed ID: 30335697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The epidemiology of non-alcoholic fatty liver disease.
    Bellentani S
    Liver Int; 2017 Jan; 37 Suppl 1():81-84. PubMed ID: 28052624
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
    Perumpail RB; Wong RJ; Ahmed A; Harrison SA
    Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The characteristics and risk factors of hepatocellular carcinoma in nonalcoholic fatty liver disease without cirrhosis.
    Tobari M; Hashimoto E; Taniai M; Kodama K; Kogiso T; Tokushige K; Yamamoto M; Takayoshi N; Satoshi K; Tatsuo A
    J Gastroenterol Hepatol; 2020 May; 35(5):862-869. PubMed ID: 31597206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: A Bidirectional Relationship.
    Muzica CM; Sfarti C; Trifan A; Zenovia S; Cuciureanu T; Nastasa R; Huiban L; Cojocariu C; Singeap AM; Girleanu I; Chiriac S; Stanciu C
    Can J Gastroenterol Hepatol; 2020; 2020():6638306. PubMed ID: 33425804
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis.
    Anstee QM; Targher G; Day CP
    Nat Rev Gastroenterol Hepatol; 2013 Jun; 10(6):330-44. PubMed ID: 23507799
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Moderate alcohol consumption is associated with advanced fibrosis in non-alcoholic fatty liver disease and shows a synergistic effect with type 2 diabetes mellitus.
    Blomdahl J; Nasr P; Ekstedt M; Kechagias S
    Metabolism; 2021 Feb; 115():154439. PubMed ID: 33246008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Natural History of Nonalcoholic Fatty Liver Disease-An Evolving View.
    Lindenmeyer CC; McCullough AJ
    Clin Liver Dis; 2018 Feb; 22(1):11-21. PubMed ID: 29128051
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan.
    Akuta N; Kawamura Y; Suzuki F; Saitoh S; Arase Y; Kunimoto H; Sorin Y; Fujiyama S; Sezaki H; Hosaka T; Kobayashi M; Suzuki Y; Kobayashi M; Ikeda K; Kumada H
    Hepatol Int; 2016 Jul; 10(4):647-56. PubMed ID: 27074850
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
    Massoud O; Charlton M
    Clin Liver Dis; 2018 Feb; 22(1):201-211. PubMed ID: 29128057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonalcoholic fatty liver disease and hepatocellular carcinoma.
    Zoller H; Tilg H
    Metabolism; 2016 Aug; 65(8):1151-60. PubMed ID: 26907206
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study.
    Vilar-Gomez E; Calzadilla-Bertot L; Wai-Sun Wong V; Castellanos M; Aller-de la Fuente R; Metwally M; Eslam M; Gonzalez-Fabian L; Alvarez-Quiñones Sanz M; Conde-Martin AF; De Boer B; McLeod D; Hung Chan AW; Chalasani N; George J; Adams LA; Romero-Gomez M
    Gastroenterology; 2018 Aug; 155(2):443-457.e17. PubMed ID: 29733831
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A young patient with type 2 diabetes associated non-alcoholic steatohepatitis, liver cirrhosis, and hepatocellular carcinoma.
    Michel M; Kalliga E; Labenz C; Straub BK; Wörns MA; Galle PR; Schattenberg JM
    Z Gastroenterol; 2020 Jan; 58(1):57-62. PubMed ID: 31931541
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies.
    Stefan N; Häring HU; Cusi K
    Lancet Diabetes Endocrinol; 2019 Apr; 7(4):313-324. PubMed ID: 30174213
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Extrahepatic Diseases and NAFLD: The Triangular Relationship between NAFLD, Type 2-Diabetes and Dysbiosis.
    Scorletti E; Byrne CD
    Dig Dis; 2016; 34 Suppl 1():11-8. PubMed ID: 27548822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.